CytoDyn, Inc.

ACTIVE

华盛顿州克拉克县, 华盛顿州, United Stateswww.cytodyn.comPublic11–50 employeesEstablished: 2002-01-01

Clinical Trials

2 active

Approvals

Total approvals

Agencies

Regulatory bodies

Founded

2002

Overview

Trial Phase Distribution

Phase

Trials

Phase 2

72.0%

Phase 1

12.0%

Trial Status Distribution

Active, not recruiting

8.0%

Available

4.0%

Completed

52.0%

No Longer Available

4.0%

Terminated

20.0%

Unknown

4.0%

Withdrawn

8.0%

Clinical Trials

Trials sponsored by this organization (25)

CLOVER - CCR5-targeting Leronlimab With Oral Chemotherapy and VEGF-inhibitor Enriched Regimen

Phase 2

Active, not recruiting

interventional

Jun 202566 participants

Leronlimab in Combination With Regorafenib in Patients With CCR5+, Metastatic Colorectal Cancer

Double Blind, Placebo Controlled Study of Safety and Efficacy of Leronlimab in Patients With "Long" COVID-19

Phase 2

Completed

interventional

Mar 202156 participants

Leronlimab (PRO 140) in Patients With Nonalcoholic Steatohepatitis

Phase 2

Completed

interventional

Dec 202087 participants

A Phase 2b/3 Study to Evaluate the Efficacy and Safety of Leronlimab for Patients with Severe or Critical Coronavirus Disease 2019 (COVID-19)

Phase 1

Active, not recruiting

May 2020290 participants

Basket Study of Leronlimab (PRO 140) in Patients With CCR5+ Locally Advanced or Metastatic Solid Tumors

Phase 2

Completed

interventional

May 202016 participants

Evaluate the Efficacy & Safety of Leronlimab in Patients With Severe or Critical COVID-19

Phase 2

Completed

interventional

Apr 2020484 participants

Study to Evaluate the Efficacy and Safety of Leronlimab for Mild to Moderate COVID-19

Phase 2

Completed

interventional

Apr 202086 participants

Page 1 of 4

Approvals

No approval data available

News

No news articles found

Back to Organizations